The company has jointly established the "Cross-Strait Joint Research Institute" with Taiwan's Chung-Hwa Research Institute to integrate scientific research resources on both sides of the strait, focus on cutting-edge technologies, and create a new drug research and development center for multiple dosage forms. Through in-depth cooperation, we will continue to expand the boundaries of technology and promote the development and industrialization of innovative drugs.
The company attaches great importance to talent cultivation. Over the past 30 years, it has built an experienced and skilled independent research and development team. With solid scientific research capabilities and rich project experience, the company has successfully obtained more than 100 domestic production approvals, covering a variety of therapeutic areas. In addition, we have worked closely with Japanese customers and accumulated rich experience in the joint application of prescription drugs and OTC drugs, demonstrating our international research and development capabilities.
In the future, the company will continue to be driven by technological innovation, deepen industry-university-research cooperation, and contribute more high-quality solutions to the global pharmaceutical and health industry!
We always insist on driving production with high standards, and ensure that every drug and every tablet meets the quality requirements through intelligent and automated advanced equipment combined with a strict quality management system. At the same time, the international certification qualification of the base has laid a solid foundation for us to expand the global market and help the company become a trustworthy international pharmaceutical company.
In the future, we will continue to optimize production processes, improve production efficiency, and use our strong production capabilities to provide safer and higher-quality medicines to patients around the world!